Compounds · Semaglutide · continued

Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? posts 61–63

Compounds › Semaglutide randomised trial type 2 diabetes STEP programme effect size Solved

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

OkaforTL3Regular5 Dec 2024#61

Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.

The short answer was in the first line; everything after is the working.

14 likes 20mo

n.szaboTL25 Dec 2024#62

steady_state, post #49: Building on post #48 rather than restating it. Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather than a forum summary. Go to post

Post #60 and I disagree about the size of the effect, not about the direction.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

I have seen it go both ways, which is why I hedge.

29 likes in reply to #49 20mo

a.stephanopoulosTL3Regular6 Dec 2024 · edited#63

b.dumitru, post #8: Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed. That is the version I use.… Go to post

Narrowing post #62, because the general version has more than one answer.

The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is the pharmacological argument for the four-week step interval.

0 likes in reply to #8 20mo

Promoted into the documentation commons. The content of this topic is maintained at Liraglutide — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Moved from Retatrutide by hana.sato. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

Topic	Participants	Replies	Views	Activity
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? Compounds › Semaglutide effect size type 2 diabetes STEP programme SELECT trial Solved Closed Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in…	+94	102	14k	19mo
The C-cell question: rodent findings and their human context — what changed since Compounds › Semaglutide effect size SELECT trial randomised trial type 2 diabetes Closed The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of c-cell question…	+61	65	1.3k	22mo
Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…	+2	6	18k	17mo
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people here…		2	10k	3mo
Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide effect size type 2 diabetes SELECT trial Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because…		2	14k	2mo

Related topics — sharing the tags randomised trial, type 2 diabetes, STEP programme

Topic	Participants	Replies	Views	Activity
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…	+122	136	48k	9mo
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on…		2	17k	6h
Gallbladder disease risk with rapid weight loss Clinical › Comorbidities obstructive sleep apnoea type 2 diabetes chronic kidney disease Solved Posting this under the heading it deserves: Gallbladder disease risk with rapid weight loss Everything below is what sits behind that. Gallbladder disease risk — I have the observation and I do not trust my…	+56	63	34k	18mo
Second pass at: Historical amylin analogues and what happened to them Compounds › Cagrilintide & amylin analogues amylin analogues effect size cagrilintide cagrisema Closed Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. The question about Historical amylin analogues that I actually want…	+15	19	22k	18mo
The arithmetic of an intermediate dose between two label steps Practice › Dosing & titration dose reduction semaglutide missed dose On the subject in the title: The arithmetic of an intermediate dose between two label steps Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am…		2	136	2mo